Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-Lynch: DC Vaccination for Tumour Prevention in Lynch Syndrome
NCT07412197Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Lynch syndrome (LS), sponsored by Radboud University Medical Center. Primary endpoints: Treatment-Related adverse events at 2 years and Neoantigen-specific T cells induction at 4 years. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT07412197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412197.